MaaT Pharma
Financing Rounds
- Series B
- Public
Round Led by Symbiosis
Round Led by Symbiosis
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. The Company’s powerful discovery and analysis platform, gutPrint®, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.
View Website
Modality
- Biologic
Indications
- Immunology
- Oncology
Development Status
- Phase 3+